Description:
In recent decades, genetic technologies for research and diagnostics have transformed healthcare, offering new possibilities in precision medicine and disease management. Next-generation sequencing (NGS) has revolutionized genetic disease diagnostics and oncology, providing comprehensive insights at a relatively low cost. PCR continues to evolve, remaining a central tool in molecular diagnostics. In situ hybridization techniques (ISH) like FISH are crucial for understanding gene expression and genetic alterations in situ.
Stay ahead of the competition with comprehensive market insights on genetic technologies and molecular diagnostics from Kalorama Information in Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028. Order your copy of the report to gain unparalleled knowledge on the top companies, technologies, and market trends shaping the future of healthcare.
Key Highlights:
- Cancer testing is advancing towards precision medicine, utilizing numerous biomarkers for precise diagnosis, therapy selection, and monitoring. Growth rates in cancer testing surpass other IVD fields.
- Breakthroughs in rare inherited/genetic diseases and Non-Invasive Prenatal Testing (NIPT) are transforming healthcare.
- The report covers market data for molecular testing in oncology, rare inherited/genetic diseases, and NIPT. It includes segments such as oncology assays, colon cancer molecular screens, ISH/FISH, HPV, and CTCs.
Regional Market and Forecast:
- North America leads in these areas of testing but is experiencing slightly lower growth rates compared to APAC and ROW.
- The report provides market sizing and forecasts for regions worldwide, including Asia Pacific, Europe, America, and RoW.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Molecular Diagnostics in Oncology, Genetic, NIPT, Market Revenues Forecast, 2023-2028 (in millions $)
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR |
| Oncology assays (incl. CDx) |
$XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Colon cancer molecular screen | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| ISH/FISH | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| HPV | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Prenatal testing – NIPT | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Genetic/inherited disease assays |
$XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| CTCs | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Total | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
Source: Kalorama Information
